Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Amgen
(NQ:
AMGN
)
309.89
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Amgen
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
37
38
Next >
US Stocks Eye Higher Open As Meta Q1 Uplifts Tech Sector: Analyst Says 'No Earnings Recession In Cards Yet'
April 27, 2023
Tech earnings could come to the market’s rescue on Thursday, with all major index futures currently trading higher.
Via
Benzinga
If You Invested $100 In This Stock 15 Years Ago, You Would Have $600 Today
April 26, 2023
Via
Benzinga
Why Shares of Arrowhead Pharmaceuticals Are Up Tuesday
April 25, 2023
The clinical-stage biotech announced promising news regarding a potential therapy for inflammatory pulmonary diseases.
Via
The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
April 24, 2023
Via
Benzinga
A Look Into Amgen's Debt
April 18, 2023
Via
Benzinga
Price Over Earnings Overview: Amgen
April 17, 2023
Via
Benzinga
Where Amgen Stands With Analysts
April 14, 2023
Via
Benzinga
1 Dividend Growth Stock to Buy Hand Over Fist
March 31, 2023
Investing in dividend stocks, particularly those that raise their payouts regularly, can pay off massively in time.
Via
The Motley Fool
Thinking Of Buying Healthpeak Properties? Here Are The Properties And Tenants You'd Be Adding To Your Portfolio
April 21, 2023
Real estate investment trusts (REITs) are one of the most popular income-oriented types of stocks investors can purchase. Receiving monthly or quarterly dividend payments on a regular basis is...
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
April 19, 2023
Via
Benzinga
As Its Stock Gets Set For Upgrade, Boan Biotech Still Faces Two Big Risks
April 18, 2023
Key Takeaways: With two products now generating revenue, Boan Biotech will soon have the “B” marker for high-risk tickers removed from its stock symbol Boan faces stiff competition in its main area of...
Via
Benzinga
Cancer And Diabetes Remain Among The Deadliest And Most Debilitating Diseases — Is Gene Therapy The Solution? One Company, Genprex, Inc. (NASDAQ: GNPX), Thinks So
April 18, 2023
On their own, cancer or diabetes can be debilitating and deadly. The two are common diseases with tremendous impact on health worldwide.
Via
Benzinga
Amgen's Debt Overview
March 31, 2023
Via
Benzinga
A Look Into Amgen Inc's Price Over Earnings
March 30, 2023
Via
Benzinga
7 Dividend Stocks to Buy That Are Backed by Strong Cash Flows
April 16, 2023
Cash is king and this article highlights seven dividend stocks with strong cash flows and an emphasis on free cash flow.
Via
InvestorPlace
Novo Nordisk Surges To Another Record As Obesity Drugs Drive Higher Outlook
April 13, 2023
Demand for Wegovy and Ozempic prompted Novo to raise its full-year outlook.
Via
Investor's Business Daily
Red-Hot Obesity-Drug Maker Novo Nordisk Soars To Record On A $725 Million Deal
April 12, 2023
Novo Nordisk is already a leader in obesity treatment with Saxenda and Wegovy.
Via
Investor's Business Daily
These 3 Health Care Stocks Delivering High-Dividend Yields Are Recommended By Wall Street's Most Accurate Analysts
April 12, 2023
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Via
Benzinga
Can You Still Buy the Dow Jones' Best-Performing April Stocks?
April 10, 2023
Each is benefiting from recent good news, but there's also a theme-based tailwind brewing that could last a while.
Via
The Motley Fool
Love Dividends? These 3 Stocks Are Smart Buys Right Now
April 09, 2023
With yields of 3.1%, 3.4%, and 14.3%, these stocks are hard to pass up right now.
Via
The Motley Fool
Week In Review: Suzhou Duality Out-Licenses Two ADCs To BioNTech In $1.7 Billion Deal
April 08, 2023
Duality Biologics out-licensed global rights (ex-China) for two ADC candidates to BioNTech, Pfizer’s partner, for one of the two original COVID-19 vaccines in a deal worth $170 million upfront and up...
Via
Talk Markets
7 Very Undervalued Penny Stocks to Buy in April 2023
April 06, 2023
Undervalued penny stocks present investors who are very bullish on the near-term future with a high-risk, high-reward option.
Via
InvestorPlace
Income Investors: These 2 Stocks Have Quadrupled Their Dividend Payouts Over the Past 10 Years
April 06, 2023
These two stocks have generated massive dividend growth for shareholders in the last decade.
Via
The Motley Fool
3 Must-Buy Dow Stocks for Your April Buy List
April 05, 2023
The range of Dow stocks to choose from is small, but there are plenty of great opportunities for investors to choose from.
Via
InvestorPlace
3 Dow Stocks With Above-Average Dividends Yields to Buy in April
April 03, 2023
Income-seeking investors are going to love the annual payout raises and yields of 2.9% or better that these legendary dividend payers offer right now.
Via
The Motley Fool
Amgen Options Traders Betting On Stock Rising This Much By April Expiration
March 30, 2023
Within the next month, Amgen Inc. (NASDAQ: AMGN) is expected to report quarterly earnings at $4 per share on revenue of $6.26 billion, analysts say.
Via
Benzinga
This Blue Chip Dividend Stock Should Return to Form When the Risk Premium Flips
March 30, 2023
T-bills may be the flavor of the month, but history has shown this top biotech stock is a far better long-term investment.
Via
The Motley Fool
The Government Move That Could Drive Obesity Drugs — And Lilly, Novo Shares
March 29, 2023
The decision from the WHO could further bolster use of Novo's Saxenda and Wegovy.
Via
Investor's Business Daily
Up 463%, This Sizzling Growth Stock Could Have a Lot More Room to Run
March 29, 2023
Viking Therapeutics stock might in the midst of a historic run.
Via
The Motley Fool
Viking Therapeutics' Initial VK2735 'Data Resoundingly Beat Expectations,' Analyst Says
March 28, 2023
Earlier today, Viking Therapeutics Inc (NASDAQ: VKTX) announced the first-in-human single-ascending dose and multiple-ascending dose data of VK2735.
Via
Benzinga
< Previous
1
2
...
12
13
14
15
16
17
18
19
20
...
37
38
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.